Ultrasound could replace colonoscopies for Crohn's patients on new drug
NCT ID NCT07308067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how quickly risankizumab (Skyrizi) heals deep intestinal damage in people with Crohn's disease. Instead of repeated colonoscopies, researchers use intestinal ultrasound to track healing at 4 and 12 weeks. The goal is to find a simpler, more comfortable way to monitor treatment success. About 109 adults with Crohn's disease who are starting risankizumab will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amiens university hospital
Amiens, France
-
Clermont-Ferrand University hospital
Clermont-Ferrand, France
-
Grenoble university hospital
Grenoble, France
-
Marseille University Hospital
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- Which diet do IBD patients prefer? intermittent fasting, mediterranean, or low FODMAP?
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- Which biologic best stops Crohn's from coming back after surgery?
- New biologic mirikizumab put to the test against standard therapies for IBD
- Blood and stool tests could revolutionize IBD monitoring